Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Arixa: Breaking resistance with oral beta lactamase inhibitors

Arixa's prodrug chemistry for oral beta-lactamase inhibitors

Arixa has made an IV antibiotic oral with prodrug chemistry.

Arixa Pharmaceuticals Inc. is modifying diazabicyclooctanes, a class of β-lactamase inhibitors that suffer from poor absorption across the GI tract, for use in combination with β-lactam antibiotics to treat Gram-negative infections.

No oral β-lactamase inhibitors have received FDA approval since the first in 1984: clavulanate. And, according to Arixa

Read the full 583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers